Vertex non-opioid painkiller Journavx gets mixed ICER review
ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...
Nasdaq1mon
Vertex, Inc. Reports Q4 2024 Financial Results with 15.2% Revenue Growth and Strategic Investments for Future Growth
Vertex's total revenues for Q4 2024 were $ ... under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, to be filed with the ...